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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 

























• To address the research 
gap, and understand if 
individuals who have 
recovered from COVID-
19 are protected from 
future infection, a large 
multicentre, prospective 
cohort study was 
conducted in the UK. 
• 30 625 participants were 
enrolled on the study to 
be followed up for 1 year. 
Symptomatic 
questionnaire were 
completed every 2 
weeks, with antibody 
testing and Nucleic Acid 
Amplification Testing 
done at baseline and 
routinely throughout the 
study. 32.3% of 
participants were positive 
at baseline and formed 
the positive cohort; at 7 
months post follow up, 
the study identified 153 
possible reinfections, 






reinfection in this cohort. 
In the negative cohort, 
1704 new infections 
were identified in the 7 
month period. The 
authors report that 
previous infection 
reduced the incidence of 
















• This study explores the 
incidence, association 
and risk factors for the 
development of post- 
Covid-19 syndrome. 400 
participants with a 
diagnosis of COVID-19 




followed up for one 
month post discharge 
from hospital. 
• From the 355 patients 
followed up via 
telephone interview, 46% 
reportedly had post-
Covid-19 symptoms, with 
fatigue being the most 
prevalent symptom 
(70%). Post-Covid-19 
symptoms were higher 
amongst females, those 
who required a long time 
to achieve clinical 
improvement and those 
who presented with 
severe disease. The 
authors conclude that 
patients hospitalised and 
discharge with Covid-19 

























• Five case studies 
from Oslo, 
Norway are 
reported of health 
care workers (32-




a 7-10 days 
following their 
first dose of 
ChAdOx1 nCoV-
19 vaccine. Four 








died. At that time 
a total of 132,686 
persons in 
Norway had 
received the first 
dose of the 
ChAdOx1 nCoV-
19 vaccine. 
• The authors 
conclude that 










, case study 
  






















• The authors identify that 
there has been poorer 
maternal, foetal and 
neonatal outcomes 
including an increase in 
maternal and foetal 
mortality, increase in still 
births, ruptured ectopic 
pregnancies and maternal 
mental health during the 
COVID-19 pandemic. This 
has disproportionately 
affected LMICs, however 
more publications were 
from HIC settings. Poorer 
outcomes in LMICs and 
HICs were highest 
amongst vulnerable 
populations. Maternal 
stress and postnatal 
depression was also 
increased. An increase in 
still births was reported in 
LMICs but not HICs. 
Overall analysis showed 
no increased in preterm 
births but data suggests 
there was a decrease in 
preterm births in HICs. 
• A systematic review and 
metanalysis was 
conducted using Medline 
and Embase to search 
articles from January 2020 
to January 2021. 
• The authors suggest that 
limited access to maternity 
services, redeployment of 
maternity staff and fear of 
contracting COVID-19 
may have contributed to 
less engagement with 
maternity services and 
poorer outcomes. More 
so, wider society changes 
including increased 









and poverty may have 
contributed.   
• The authors conclude that 
safe and accessible 
maternal care must be 
prioritised during and 
following the pandemic, 























• This policy brief 
considers key issues 





during the COVID-19 
response in four urban 
contexts across India. 
In emergencies, 
technology used in 
public health 
interventions have the 
potential to worsen 
existing inequalities 
and therefore 
interventions should be 
evaluated exploring 
their appropriateness, 
inclusive outcomes for 
marginalised urban 
populations and 
consideration of the 
balance between 
surveillance and 
control, and privacy 
and citizen autonomy. 
• This policy brief was 
developed through 
dialogue with national 
and city authorities and 
key city stakeholders. 
• Access to devices, 








literacy should be 
considered, as well as 
data protection, 
transparency and trust. 
Local need and reality 
should be 



















• This policy brief 
considers key 
recommendations 
for  COVID-19 
response and recovery 
to mitigate impacts of 
the pandemic for 
indigenous people in 
South America (focus 
on the Amazon), who 
have been 
disproportionately 
affected. Drawing on 
public statements and 
other documents from 
indigenous 
organisations and civil 
society network, the 
brief identifies key 
principles. Principles 
include: 































right to isolation 





• Based on these 
principles, key 
considerations for 




heterogenous, and the 
brief considers different 
contexts and 
vulnerabilities such as 





be adapted to the local 
context and engage 
with indigenous people 
and leaders for 
immediate and longer- 
term response. This 
guide can be used as a 





strategies for Covid-19 
response and recovery.  
  



























• A team of international 
experts from WHO and 
China convened “to 
identify the zoonotic 
source of the virus and 
the route of introduction 
to the human population, 
including the possible 
role of intermediate 
hosts, including through 
efforts such as scientific 
and collaborative field 
missions” 
• This is the report of the 
international team on the 
Wuhan field visit, from 14 
January to 10 February 
2021 by a joint WHO-
China study team 
conducted over a 28 day 
period and explored 
epidemiology, animals 
and the environment 
and  molecular 
epidemiology and 
bioinformatics.  
• Following the report 
WHO Director-General 
highlights that the 
source of the virus has 
not yet been found and 
all hypotheses remain 
on the table. This single 
research trip is just the 
start to finding the origin 
of the virus so that 
collectively steps can 
be taken “to reduce the 
risk of this happening 
again” 
• The epidemiology 
working group analysed 
surveillance data from 
Wuhan in late 2019. In 
addition to national 
sentinel surveillance 
data; laboratory 








and reports of retail 
pharmacy purchases for 
antipyretics, cold and 
cough medications, 
stored research samples 
from across Hubei 
Province were also 
analysed. No evidence of 
mortality or 
morbidity  due to SARS-
CoV-2 was found before 
the reported outbreak. 
• Whilst many early cases 
of COVID-19 were 
associated with Huanan 
market, other cases were 
associated with other 
markets, and some with 
no markets, therefore the 
report suggests that ‘no 
firm conclusion therefore 
about the role of the 
Huanan market in the 
origin of the outbreak, or 
how the infection was 
introduced into the 
market, can currently be 
drawn’ (page 7). 
• Genomic data of virus 
from animals were also 
studied. Whilst bats and 
pangolins are a potential 
reservoir, no direct 
progenitor has been 
identified. The animal 
and environment working 
group sampled and 
tested from 80, 000 
wildlife, livestock and 
poultry, across 31 
provinces. 
• From the molecular 
sequence data, most 
estimates suggest the 
outbreak may have 
started mid November to 
early December 2019, 
but this is not considered 
by the report as 
conclusive.  
• Evidence from recent 
outbreaks in China 
have been linked to 
cold-chain products. 
This was not 
considered early in the 
pandemic and now is 
being considered as a 
possible pathway, along 
with other potential 





















• A series of 
articles have 
been produced 
which reflect on 






there may be to 






This article was 
included as part 





• This article 


































































others due to 
socio-economic 
status, age or 
occupation. 





































• In conclusion, 
public health 
responses need 
to be innovative 


















































have been a 





























survey and a 
rapid literature 
review. 
• A series of 
articles have 
been produced 
which reflect on 






there may be to 






This article was 
included as part 
of this series 
(see Editorial 
below). 






















Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
09.04.2021 Military coup during COVID-19 pandemic and 
health crisis in Myanmar 
BMJ Global Health| 
Commentary 
08.04.2021 Leadership, collaboration and using data science 
to fight COVID-19 in the WHO African region 
Epidemiology & Infection| 
Editorial 
08.04.2021 Covid-19: Brazil breaks record daily death toll as 
crisis spreads through South America 
The BMJ| News 
08.04.2021 AstraZeneca vaccine: Blood clots are “extremely 
rare” and benefits outweigh risks, regulators 
conclude 
The BMJ| News 
05.04.2021 The catastrophic Brazilian response to covid-19 
may amount to a crime against humanity 
The BMJ| Opinion 
April 2021 Planetary healthy publics after COVID-19 The Lancet Planetary 
Health | Personal View 
(Hinchliffe. S, Manderson. L 
and Moore. M) 
April 2021 Vaccine certificates: does the end justify the 
means? 
The Lancet Microbe| 
Editorial 
April 2021 Behind Cuba's successful pandemic response The Lancet Infectious 
Diseases| News desk 
April 2021 Vacuna-gate escalates in Peru The Lancet Infectious 
Diseases| News desk 
April 2021 Ebola and COVID-19 in DR Congo and Guinea The Lancet Infectious 
Diseases| News desk 
01.04.2021 Preparing for the next pandemic requires public 
health focused industrial policy 
The BMJ| Opinion 
01.04.2021 Covid-19: Ivermectin’s politicisation is a warning 
sign for doctors turning to orphan treatments 
The BMJ| Feature 
01.04.2021 Covid-19: Brazil’s spiralling crisis is increasingly 
affecting young people 
The BMJ| News 
01.04.2021 After the WHO report: what’s next in the search for 
COVID’s origins 
Nature| News Explainer 
31.03.2021 The Pfizer-BioNTech Vaccine Is Said to Be 
Powerfully Protective in Adolescents 
New York Times| News 
30.03.2021 WHO calls for further studies, data on origin of 
SARS-CoV-2 virus, reiterates that all hypotheses 
remain open 
World Health Organisation| 
News 
29.03.2021 Initial report of decreased SARS-CoV-2 viral load 
after inoculation with the BNT162b2 vaccine 
Nature| Brief 
Communication 
29.03.2021 Africa Signs Historic Agreement with Johnson & 
Johnson for 400 Million Doses of COVID-19 
Vaccines 
UNECA| Press release 
25.03.2021 Introduction – Building Back a Better World: The 
Crisis and Opportunity of Covid-19 
IDS Bulletin| Editorial  
25.03.2021 Building a Better World: The Crisis and Opportunity 
of Covid-19 
IDS Bulletin | Articles 
   
 
Dashboards & Trackers    












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs  







Health Topics   Social 
Sciences 
WHO COVID-
19 pandemic  
Africa CDC Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 







  IDA 











































































Institute of Public 
Health 
    





Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The 
Lancet 
 HEART     




 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 
  Science  Health systems 
Global 




  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  












      
WorldPop           
Flowminder           





    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
15.04.2021 How can evaluation 
work support greater 
vaccine equity for 
COVID-19? 
Webinar 1h Itad 
12.04.2021 COVID-19: Vaccines 
Safety Webinar - 
Understanding the Facts 
& Myths 
Webinar 1.5h Asia Pacific 
Association of 
Allergy, Asthma and 
Clinical Immunology 
07.04.2021 Public webinar 'The 
RECOVERY Trial: one 
year on' 
Webinar 1h Nuffield Department 
of Population Health 
25 March 
2021 
UK Public Health Rapid 
Support Team: Latest 
research & scientific 
insights 
Webinar 1h LSHTM 
18 March 
2021 
Africa taking charge of 
its future: prioritizing 
gender equality in the 
path to recovery 
Webinar 1h 30 CGD 
10 March 
2021 
Equity and scale in 
global immunization: 
new evidence from 
Nigeria on cash 
transfers for vaccination 
Webinar 1h 15 CGD 
9 March 
2021 
COVID-19 vaccines and 
Africa: where do we 









Diseases in the COVID 
era 




training for health 
workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during the 
COVID-19 pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply chain 
resilience and global 
trade 
Webinar 1h CGD 
03.12.2020 More money for health 
services: What is the 
tole of PFM in the “new 
normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental wellbeing 
of community health 
workers on the COVID-
19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the pandemic 
with a gender lens 
Live Twitter 
conversation 
  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to promote 
sharing of experience 
and expertise around 
the maintenance of 
essential health services 




starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the Economic 
and Health Impact of 
COVID-19 across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
Online courses Varies WHO 
emergencies, now offers 
10 online courses 










Nursing in Times of 
Crisis 






School of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 




Modelling and Policy 
Online learning 2 weeks 








11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 




Virtual Evidence Weeks 5 sessions 1h 30 International Initiative 











COVID-19 Open online 
brief with Dr David 
Nabarro 





Online learning 3 hours WHO 
COVID-19: methods for 
detection, prevention, 




19: Real-time training 
for the coronavirus 
disease outbreak 







COVID-19: Tackling the 
Novel Coronavirus 
Online learning 3 weeks 
















Online learning 3 weeks 







COVID-19 Critical Care: 
Understanding and 
Application 
Online learning 5 weeks 





Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary 
research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease 
control and health system responses are included. Articles related to tackling the secondary impacts on other 
sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on 
relevance. 
  
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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